Iron infusion safety check: rare blood disorder studied in 50 patients
NCT ID NCT06309641
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether intravenous iron treatments (ferric carboxymaltose or ferric derisomaltose) can cause a rare side effect called methemoglobinemia, where blood can't carry oxygen properly. Researchers measured methemoglobin levels in 50 anemic patients before and after treatment. The goal was to understand if this side effect occurs and how it relates to drug dose or patient age.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center of Clinical Research Dalarna
Falun, 79182, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug that boosts red blood cells help anemia in kidney disease?
- Could a common heart drug help kids on dialysis fight anemia?
- Can a drug free myelofibrosis patients from frequent blood transfusions?
- Could heart failure drugs boost oral Iron's power against anemia?
- Could a painless light sensor replace the needle for anemia screening?
- Waiting to clamp the cord: could 30 seconds save preterm babies?